Brokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $14.75

DBV Technologies S.A. (NASDAQ:DBVT) has earned an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $14.75.

DBVT has been the subject of a number of analyst reports. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research note on Friday, July 18th. The Goldman Sachs Group upgraded shares of DBV Technologies to a “sell” rating and set a $7.25 target price for the company in a research report on Thursday, May 29th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Tuesday, May 27th. Lifesci Capital upgraded shares of DBV Technologies to a “strong-buy” rating in a research report on Thursday, June 26th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price on shares of DBV Technologies in a report on Thursday, June 26th.

DBV Technologies Stock Performance

Shares of DBV Technologies stock opened at $9.87 on Wednesday. The firm has a 50-day moving average of $9.73 and a 200-day moving average of $8.49. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $12.78. The stock has a market cap of $270.44 million, a PE ratio of -2.07 and a beta of -0.36.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $0.64 million. DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%. Equities research analysts predict that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Octagon Capital Advisors LP acquired a new stake in DBV Technologies during the 2nd quarter worth approximately $9,315,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of DBV Technologies during the second quarter worth $9,659,000. MPM Bioimpact LLC bought a new stake in shares of DBV Technologies in the second quarter worth $9,649,000. Vivo Capital LLC acquired a new stake in DBV Technologies in the second quarter valued at $9,659,000. Finally, Nan Fung Trinity HK Ltd. bought a new position in DBV Technologies during the 2nd quarter worth $340,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.